Evidence map›Paper›PMID 40092846›Full record

ArticleInfection and drug resistance2025

Rebound of Antibiotic Use and Respiratory Infections After Resumption of Normalcy From COVID-19 in Hong Kong.

Edmond Siu-Keung Ma, Enoch Hsu, Vincent Chow, Tracy Chow, K H Kung, Albert Au, Hong Chen

Abstract read
In one paragraph

Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Universal decolonization for methicillin-resistantPublic health in practice (Oxford, England) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Macrolide-ResistantMicroorganisms · 2025
    Article
  8. Epidemiological and Antimicrobial Resistance Trends ofInfection and drug resistance · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Edmond Siu-Keung MaInfection Control Branch, Centre for Health Protection, Department of Health, Hong Kong, Special Administrative Region, People's Republic of China.ORCID 0000-0003-3071-6256
Enoch HsuInfection Control Branch, Centre for Health Protection, Department of Health, Hong Kong, Special Administrative Region, People's Republic of China.ORCID 0000-0002-9163-9218
Vincent ChowInfection Control Branch, Centre for Health Protection, Department of Health, Hong Kong, Special Administrative Region, People's Republic of China.ORCID 0009-0001-6547-9871
Tracy ChowInfection Control Branch, Centre for Health Protection, Department of Health, Hong Kong, Special Administrative Region, People's Republic of China.
K H KungCommunicable Disease Branch, Centre for Health Protection, Department of Health, Hong Kong, Special Administrative Region, People's Republic of China.
Albert AuCommunicable Disease Branch, Centre for Health Protection, Department of Health, Hong Kong, Special Administrative Region, People's Republic of China.
Hong ChenInfection Control Branch, Centre for Health Protection, Department of Health, Hong Kong, Special Administrative Region, People's Republic of China.ORCID 0000-0001-8854-2119

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: During COVID-19 pandemic, use of antimicrobial has been shown to be reduced coupled with various respiratory infections. We investigated whether this effect on reduction of antibiotic prescription can be sustained after resumption of normalcy and lifting of public health measures. Methods: We compared the wholesale supply of antimicrobials using mean annual Daily Defined Dose/1000 inhabitants (DID) in different sectors in pre-COVID-19 (2014-2019), COVID-19 (2020-2022) and post-COVID-19 (2023) periods. We grouped the data according to AWaRe categorisation namely Access, Watch and Reserve defined by WHO, and analysed the trends of the top 10 antibiotics and broad-spectrum antimicrobials. The trends in statutory notifiable diseases including scarlet fever, pneumococcal infections, chickenpox, tuberculosis, and pertussis and influenza-like-illness detected by sentinel surveillance system was analysed by negative-binominal regression. Results: Compared to baseline level, an overall reduction of 27.2% of antimicrobial utilization was observed during the pandemic years, with a rebound recorded in 2023, up to 89.5% of the pre-pandemic level. The access group of antimicrobials accounted for 57.9% in 2014 gradually increased to 60.2% in 2023 across the pandemic years. Concurrently, reduction in incidence of scarlet fever, pneumococcal infections, chickenpox, tuberculosis, pertussis and influenza-like-illness was observed during COVID-19 pandemic with statistical decreasing trend, p<0.05 for scarlet fever, pneumococcal infections and chickenpox. Rebound in all these infections was reported in 2023, except for chickenpox which showed continued decrease in incidence. Conclusion: We demonstrated a substantial reduction of antibiotic use during the COVID-19 pandemic, which rebounded in 2023, likely due to increased incidence of respiratory diseases after lifting of public health and social measures. We urged for close monitoring of the antimicrobial resistance pattern of different bacteria due to the inter-connectiveness and global impact of these two pandemics.

Indexed as

antibioticsantimicrobial resistanceantimicrobial utilizationCOVID-19surveillance

Identifiers

PMID40092846
PMCPMC11910044

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.